Enveric Biosciences, Inc. (ENVB)
1.46
+0.04
(+2.82%)
USD |
NASDAQ |
Oct 28, 12:49
Enveric Biosciences Cash from Operations (Quarterly) : -2.444M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.444M |
| March 31, 2026 | -2.257M |
| December 31, 2025 | -1.785M |
| September 30, 2025 | -2.075M |
| June 30, 2025 | -1.890M |
| March 31, 2025 | -2.392M |
| December 31, 2024 | -1.312M |
| September 30, 2024 | -0.9271M |
| June 30, 2024 | -2.889M |
| March 31, 2024 | -2.598M |
| December 31, 2023 | -1.751M |
| September 30, 2023 | -2.740M |
| June 30, 2023 | -4.466M |
| March 31, 2023 | -5.137M |
| December 31, 2022 | -3.462M |
| September 30, 2022 | -4.550M |
| June 30, 2022 | -4.585M |
| March 31, 2022 | -4.549M |
| December 31, 2021 | -4.067M |
| September 30, 2021 | -2.206M |
| June 30, 2021 | -2.022M |
| March 31, 2021 | -3.162M |
| December 31, 2020 | |
| September 30, 2020 | -0.3937M |
| June 30, 2020 | -0.3511M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.8939M |
| December 31, 2019 | -0.4788M |
| September 30, 2019 | -0.5001M |
| June 30, 2019 | -0.49M |
| March 31, 2019 | -0.9841M |
| December 31, 2018 | -1.003M |
| September 30, 2018 | -1.283M |
| June 30, 2018 | 0.1802M |
| March 31, 2018 | -0.4596M |
| December 31, 2017 | -0.9412M |
| September 30, 2017 | -0.0986M |
| June 30, 2017 | -0.8631M |
| March 31, 2017 | -0.8379M |
| December 31, 2016 | 0.2936M |
| September 30, 2016 | -2.831M |
| June 30, 2016 | 1.400M |
| March 31, 2016 | -1.566M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | -0.0012M |
| December 31, 2014 | -0.004M |
| September 30, 2014 | 0.0013M |
| June 30, 2014 | -0.0127M |
| March 31, 2014 | -0.0278M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | -38.71M |
| Impact BioMedical, Inc. | 0.47M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 5.845M |
| Free Cash Flow | -8.561M |
| Free Cash Flow Per Share (Quarterly) | -0.6131 |
| Free Cash Flow to Equity (Quarterly) | -2.444M |
| Free Cash Flow to Firm (Quarterly) | -2.444M |
| Free Cash Flow Yield | -341.3% |